Accentia Biopharmaceuticals, Inc. (NASDAQOTH:ABPI)

CAPS Rating: No stars 0.00

A biopharmaceutical company focused on the development & commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease &, through its publicly-traded subsidiary, Biovest International Inc., oncology.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

32 Outperform
6 Underperform
 

All-Star Players

5 Outperform
1 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top ABPI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

gingerlade (56.15)
Submitted December 29, 2007

The company has a few blockbuster biopharmaceuticals in the pipeline awaitingfast track and FDA approval...SinuNase (BDSI)andRevimmune for 80 autoimmune diseases focusingfor now on relapse-remit MS....and a vaccinefor Hodgkins Lymphoma and a Biovac… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ABPI VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ABPI.

Recs

0
Member Avatar binx007 (21.25) Submitted: 3/3/2008 5:09:26 PM : Outperform Start Price: $2.43 ABPI Score: -215.14

I am bullish on this spec play. I think they are going to have some good results for us this month and after that, the SKY is the limit. Hold on to your boot straps. The down side is so small it is hard not to love the opportunity to win BIG here.

Recs

0
Member Avatar maggioli (50.13) Submitted: 1/7/2008 9:00:50 PM : Outperform Start Price: $2.60 ABPI Score: -204.75

The CEO has just given a resounding forward statement, if you wait to long you could miss the boat. If they get FDA approval on all three phase three products the sky is the limit. Buy now or cry later.

Recs

1
Member Avatar gingerlade (56.15) Submitted: 12/28/2007 8:09:34 PM : Outperform Start Price: $3.14 ABPI Score: -197.77

The company has a few blockbuster biopharmaceuticals in the pipeline awaiting

fast track and FDA approval...SinuNase (BDSI)and

Revimmune for 80 autoimmune diseases focusing

for now on relapse-remit MS....and a vaccine

for Hodgkins Lymphoma and a Biovac machine

to administer this on fast track....the

vaccine is being put out by BVTI a subsidiary

of APBI....Great potential this stock....of

course this is my humble opinion....as always

one must do their own research into this...

but once you do...you will be flabbergasted

at the potential of these multi-billion

dollar blockbusters if they pass FDA approval...Awesome promise....

Leaderboard

Find the members with the highest scoring picks in ABPI.

Score Leader

TrackJefferies

TrackJefferies (81.24) Score: +260.74

The Score Leader is the player with the highest score across all their picks in ABPI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
metaforummo 72.31 10/24/2006 Underperform 1Y $3.60 -100.00% +115.83% +215.82 0 Comment
jiminica 79.09 3/5/2007 Underperform 1Y $3.60 -100.00% +112.93% +212.93 0 Comment
LvMknMny < 20 12/8/2006 Underperform 1Y $3.43 -100.00% +109.98% +209.98 0 Comment
mrtofoo 23.36 1/7/2008 Underperform 5Y $2.67 -100.00% +106.64% +206.63 0 Comment
ursusurbanus 67.66 4/16/2007 Underperform NS $3.21 -100.00% +102.37% +202.36 0 Comment
myersfield < 20 9/20/2007 Outperform 1Y $2.68 -100.00% +92.57% -192.57 1 Comment
cgiscgis < 20 9/20/2007 Outperform 1Y $2.69 -100.00% +92.68% -192.68 0 Comment
gingerlade 56.15 12/31/2007 Outperform 1Y $3.14 -100.00% +97.77% -197.77 1 Comment
dominated < 20 1/2/2008 Outperform 3W $3.28 -100.00% +98.53% -198.52 0 Comment
bous < 20 9/11/2007 Outperform NS $2.79 -100.00% +100.70% -200.70 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJefferies 81.24 7/19/2010 Underperform NS $0.71 -99.99% +160.76% +260.74 0 Comment
TrackRodmanRen < 20 1/8/2007 Outperform NS $3.62 -80.66% -4.12% -76.54 3/25/2008 @ $0.70 0 Comment

Advertisement